🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

4/ But SUROVA went one step further. It identified something TRUST couldn’t yet: ⚠️ Surgical complications are what make the survival curves cross. In other words: frail patients who suffer complications lose the benefit of upfront surgery.

5/ Why is this so important? Because if we can predict which patients are at risk for complications... ➡️ We can individualize the initial treatment decision ➡️ We can avoid harm ➡️ We can improve survival

6/Even grade II complications negatively affect survival outcomes and represent a marker of patient frailty, as clearly illustrated by the survival curves.

7/ Combined conclusions from SUROVA + TRUST: ✅ Primary surgery gives the best long-term outcomes — if done safely ✅ NACT is a solid alternative in high-risk patients 🚨 But surgical complications are the game changer

7/ Two studies. One conclusion. One proves it through randomization, the other through real-world data. 👉 TRUST confirms. SUROVA explains. Together, they reshape clinical practice in ovarian cancer surgery

8/ Welcome to the era of personalized treatment in ovarian cancer. 🔬 Surgery first— yes, but selecting pts 📊 Data — yes, but with clinical interpretation 🤝 #SUROVA + #TRUST are the new evidence-based standard #Oncology #GyneOnc #OvarianCancer #ASCO2025 #RealWorldData #Esgo

Combined conclusions from SUROVA + TRUST: ✅ Primary surgery gives the best long-term outcomes — if done safely ✅ NACT is a solid alternative in high-risk patients 🚨 But surgical complications are the game changer #Esgo #Igcs Enrique Chacón

🔬 What did we learn from analyzing 3,500 women with advanced ovarian cancer from across the globe? SUROVA is the largest real-world study ever done on this topic. Led from Spain 🇪🇸, it may change the way we treat these patients. 👇 A thread:

🌍 56 countries. 174 hospitals. 3,500 patients. SUROVA compares two initial treatment strategies: 1️⃣ Primary debulking surgery (PDS) 2️⃣ Neoadjuvant chemotherapy (NACT) Which one leads to better survival? 📊 It depends.

🧠 We found something unexpected: The survival curves cross at 18 months. 🔺 NACT shows better outcomes early on. 🔻 PDS shows better survival in the long run. Why? The answer lies in surgical complications.

❗Even moderate complications (Grade II) lower overall survival. But more importantly: They reveal an underlying patient frailty that we often miss. 👉 If we operate without identifying that fragility, we lose the long-term survival benefit.

What if we could predict surgical frailty before treatment starts? That's exactly what SUROVA aims to do. 📱 We’ve built a pre-treatment risk calculator it is freely available to all clinicians.surovatrial.github.io/SUROVA-Risk-Ca…

🎯 SUROVA shows there’s no one-size-fits-all treatment. The key is individualization: ✔️ Disease burden ✔️ Performance status ✔️ Local resources 💡 Surgery works—only when done in the right patient.

Would you like to see the curves, maps, and tools we used in SUROVA? We’ll be posting key visuals and mini-threads in the coming days. 🔁 Retweet if you believe global collaboration can improve cancer care. #SUROVA #OvarianCancer #ESGO #RealWorldData

El 6 de junio celebramos el 10º aniversario del inicio de nuestra residencia en la Clínica Universidad de Navarra. Reencuentro emocionante, cálida bienvenida de Joseba Campos Capelastegui, reflexiones sabias de los Prof. Quiroga y Pardo, y muchas ganas de seguir construyendo juntos! ¡Nos vemos en el 20º!

📊 Impact Factor Alert! We’re proud to share that #IJGC's #ImpactFactor has increased to 4.7 in the 2024 Journal Citation Reports! 🚀 💥 We’ve also broken into the #Top10 in #Obstetrics&Gynecology, climbing from #11 to #8 📈 And we moved up 1 spot in #Oncology rankings, too!

Back to the past: should positive peritoneal cytology influence patient management in low-risk endometrial cancer? Find the answer in our editorial of the July´s lead article of IJGC Thank you Pedro T Ramirez for the opportunity! …l-journal-of-gynecological-cancer.com/article/S1048-…

#LeadArticle Positive #peritonealcytology predicts higher recurrence risk in low-risk #endometrialcancer 📉 Worse 5-year recurrence-free survival 📌 No impact on overall survival ⏩ bit.ly/4nS72Gm Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS

#Editorial Back to the past ⌛ should positive peritoneal cytology influence patient management in low-risk #endometrialcancer? Felix Boria Enrique Chacón ✅ bit.ly/40CHFOv Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists